Over 2 billion people – more than a quarter of the world population – suffer from chronic liver disease. Today, the needle biopsy remains the only diagnostic option. This method is fraught with disadvantages. It is expensive, painful, resource-intensive, samples only a tiny part of the liver and carries a bleeding/mortality risk. As such it is unsuitable for mass screening. This shortcoming - coupled with liver diseases progressing silently - results in 70% of patients going unnoticed until terminal stage (cirrhosis). HepaVue has developed the world’s first virtual liver biopsy which will make liver disease diagnosis affordable, painless, safe and more accessible. Our technology will prevent avoidable cases of liver cancer, transplantations and deaths.
Company Details
- Employees
- 2
- Founded
- 2023
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.hepavue.com
Hepavue Questions
Hepavue's website is http://www.hepavue.com
Hepavue's LinkedIn profile is https://www.linkedin.com/company/hepavuedx
Hepavue has
2 employees.
View email and phone details for 2
employees at Hepavue.
Hepavue's industry is
Biotechnology Research
Hepavue's top competitors are
Synature,
Onescope,
Recarta,
Wasteflow,
Firefly Fusion,
Dphi Space,
Pulse Partners,
Bioscibex,
Rema Hydrogen,
Brainquant.
Hepavue's categories are Biotechnology Research
Hepavue's founding year is 2023
